4 completed, 4 terminated, 3 withdrawn. 11 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 4, Terminated 4, Withdrawn 3 |
| Phase 1 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
Follow Stage IVB Rectal Cancer: new trials by email Literature Review of Stage IVB Rectal Cancer trials Research Report on Stage IVB Rectal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer Capecitabine, Laboratory Biomarker Analysis, Nintedanib - Colon Adenocarcinoma, Rectal Adenocarcinoma | Phase 1 / Phase 2 | Completed | Roswell Park Cancer Institute | 42 | 2015-05-08 | 2021-07-08 |
| Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer ziv-aflibercept, leucovorin calcium, fluorouracil - Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum | Phase 2 | Withdrawn | University of Southern California | 2015-03-01 | 2015-05-06 | |
| Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study - Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2013-03-01 | 2019-09-20 |
| A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer Capecitabine, Celecoxib, Intensity-Modulated Radiation Therapy - Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma | Phase 2 | Terminated | University of Washington | 27 | 2013-03-01 | 2018-01-16 |
| Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer linifanib - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 30 | 2011-06-01 | 2014-08-26 |
| Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer oxaliplatin, leucovorin calcium, fluorouracil - Liver Metastases, Recurrent Colon Cancer | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2011-03-01 | 2016-07-19 |
| Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer FOLFOX regimen, gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2010-12-01 | 2017-04-04 | |
| SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer ispinesib, laboratory biomarker analysis - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 64 | 2005-01-01 | 2015-03-02 |
| Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer cetuximab, bevacizumab, irinotecan hydrochloride - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 70 | 2003-12-01 | 2015-04-15 |
| Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer fluorouracil, sodium phenylbutyrate, indomethacin - Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 46 | 1997-05-01 | 2013-02-01 |
| Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis - Colon Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2016-05-20 |
Colonic Neoplasms (11) · Rectal Neoplasms (11) · Pancreatic Neoplasms (1)
Colonic Diseases (11) · Colorectal Neoplasms (11) · Digestive System Diseases (11) · Digestive System Neoplasms (11) · Gastrointestinal Diseases (11) · Gastrointestinal Neoplasms (11) · Intestinal Diseases (11) · Intestinal Neoplasms (11) · Neoplasms (11) · Neoplasms by Site (11) · Rectal Diseases (11) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Pancreatic Diseases (1)
Fluorouracil (5) · Bevacizumab (3) · Irinotecan (3) · Leucovorin (3) · Oxaliplatin (3) · Capecitabine (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · 4-phenylbutyric acid (1) · Celecoxib (1) · Cetuximab (1) · Folfox protocol (1) · Indomethacin (1) · Interferon-gamma (1) · MK 2206 (1) · Radiation (1)
National Cancer Institute (NCI) (5) · Roswell Park Cancer Institute (2) · City of Hope Medical Center (1) · University of Southern California (1) · University of Washington (1) · Vanderbilt-Ingram Cancer Center (1)
United States (11)
Afsaneh Barzi (1) · Christos Fountzilas (1) · Edmund Kopetz (1) · Jeffrey Wong (1) · Jordan Berlin, MD (1) · Leonard Saltz (1) · Max Sung (1) · Neil Segal (1) · Stacey Cohen (1) · Syma Iqbal, MD (1) · Wen Wee Ma (1)
P30CA016056 (2), N01CM00039 (1), N01CM17101 (1), N01CM17102 (1), N01CM17103 (1), N01CM17105 (1), N01CM62206 (1), P01CA043904 (1), P30CA014089 (1), P30CA015704 (1), P30CA016672 (1), U01CA069856 (1)